---

---

treatment   publishing date : 2021 - 12 - 06   

save search

---

Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency
Published: 2021-12-06 (Crawled : 23:00) - biospace.com/
TSHA | $2.355 -6.92% -7.43% 790K |

Health Technology

| -79.68% | O: 1.65% H: 0.0% C: 0.0%
treatment presentation preclinical gene therapies potential positive gene therapy pre-clinical

---

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody
Published: 2021-12-06 (Crawled : 22:00) - biospace.com/
ADAG | $2.65 -2.63% 740 |

Manufacturing

| -65.89% | O: 3.6% H: 0.0% C: 0.0%
treatment antibody

---

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
Published: 2021-12-06 (Crawled : 22:00) - biospace.com/
VTYX | $4.255 -2.18% -2.23% 600K |

Manufacturing

| -75.89% | O: -1.39% H: 0.0% C: 0.0%
treatment phase 2 trial bioscience ulcerative colitis

---

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
Published: 2021-12-06 (Crawled : 22:00) - biospace.com/
IOBT | $1.455 -1.02% -1.03% 57K |

| -86.51% | O: -5.23% H: 0.0% C: 0.0%
treatment phase 2 trial keytruda collaboration biotech iot

---

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra
Published: 2021-12-06 (Crawled : 15:00) - biospace.com/
ENLV | News | $1.52 15.15% 13.16% 130K |

Health Technology

| -79.69% | O: 6.31% H: 0.0% C: 0.0%
treatment application patent

---

Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma
Published: 2021-12-06 (Crawled : 14:30) - prnewswire.com
CTXR | $0.7199 -6.18% -6.58% 880K |

Health Technology

| -49.01% | O: 2.65% H: 0.0% C: 0.0%
treatment immunotherapy therapy cancer phase 3 t-cell enroll ontak

---

Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
Published: 2021-12-06 (Crawled : 14:30) - biospace.com/
LEGN | News | $45.205 -4.73% -4.97% 1.1M |

Health Technology

| 6.89% | O: 2.7% H: 0.0% C: 0.0%
new drug treatment application car-t drug therapy biotech iot submission cel

---

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis
Published: 2021-12-06 (Crawled : 14:30) - biospace.com/
SCYX | $1.495 -3.55% -3.68% 88K |

Health Technology

| -76.23% | O: -0.92% H: 0.0% C: 0.0%
treatment fda approval

---

Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
CYTH | $1.21 7.94% 21K |

Professional, Scientific, and T...

| -75.26% | O: 1.23% H: 0.0% C: 0.0%
alzheimer treatment fda phase 2 clearance therapeutics disease alzheimer’s alzheimer's disease alzheimer's

---

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
ACXP | $2.04 -2.29% 17K |

Professional, Scientific, and T...

| -50.84% | O: 2.41% H: 4.47% C: 2.82%
treatment phase 2 phase 2b trial infection iot enroll infections

---

GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
GHRS | $11.01 -2.57% -2.63% 45K |

Manufacturing

| -41.33% | O: 0.05% H: 29.33% C: 21.8%
treatment phase 2 research trial phase 1 depression

---

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
Published: 2021-12-06 (Crawled : 12:00) - ocutx.gcs-web.com
OCUL | News | $4.645 -7.1% -7.64% 3.9M |

Health Technology

| -23.78% | O: -5.26% H: 0.0% C: 0.0%
dry eye treatment phase 2 eye ocular eye disease trial disease topline results results topline

---

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021
Published: 2021-12-06 (Crawled : 12:00) - globenewswire.com
ADAG | $2.65 -2.63% 740 |

Manufacturing

| -65.89% | O: 3.6% H: 0.0% C: 0.0%
treatment antibody

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---